针对不同类型电网互联时互联电力变换器IPC(interconnecting power converter)控制模式复杂、控制难度大等问题,提出一种用于互联多个高压直流和高压交流子电网的IPC新型电网形成GFM(grid-forming)控制方法。该方法利用模块化多电平变换...针对不同类型电网互联时互联电力变换器IPC(interconnecting power converter)控制模式复杂、控制难度大等问题,提出一种用于互联多个高压直流和高压交流子电网的IPC新型电网形成GFM(grid-forming)控制方法。该方法利用模块化多电平变换器MMC(modular multilevel converter)同时控制其AC和DC端电压,并提出2个双端口GFM MMC控制策略。针对单端口GFM控制和所提双端口GFM控制进行仿真对比,结果表明,与单端口GFM控制相比,双端口GFM控制方法对突发事件(如线路和发电机停运等)的处理更具弹性,且不需为电网中的IPC端口选择GFM或电网跟随GFL(grid-following)的控制方式。展开更多
Objective： The aim of this study was to evaluate the efficacy of transcatheter arterial chemoembolization （TACE） combined with a Chinese compound preparation of ganfule on advanced hepatocellular carcinoma （HCC）....Objective： The aim of this study was to evaluate the efficacy of transcatheter arterial chemoembolization （TACE） combined with a Chinese compound preparation of ganfule on advanced hepatocellular carcinoma （HCC）. Methods： The study population consisted of 132 advanced HCC patients with Child-pugh NB. Tumor in all patients was involved with main trunk of portal vein and/or inferior vena cava, or local lymph node metastasis, or distant metastasis. TACE combined with ganfule were performed in 65 patients with advanced HCC （interventional treatment group）, 67 patients were treated with traditional Chinese herbal drug alone （Chinese herb group）. The prime end point was overall survival （OS）, and prognostic factors were analyzed. Results： The median OS was 205 days [95% confidence interval （CI）, 155-255 days] in interventional treatment group and 127 days （95% CI, 70-184 days） in Chinese herb group （P 〈 0.05）. The 6-month, 1-year, and 2-year OS rates were 58.9%, 29.1%, 7.7% in interventional treatment group, and 33.3%, 12.3%, 1.8% in Chinese herb group, respectively. The portal vein thrombosis, ECOG performance status （PS） were independent prognostic factors for OS. Conclusion： Ttranscatheter arterial chemoembolization combined with a Chinese compound preparation of ganfule could greatly prolong the OS of advanced HCC patients. The portal vein thrombosis and ECOG PS were independent prognostic factors for OS.展开更多
基金Supported by a grant from the Research Foundation of Fujian Provincial Health Department(No.2010-7)
文摘Objective： The aim of this study was to evaluate the efficacy of transcatheter arterial chemoembolization （TACE） combined with a Chinese compound preparation of ganfule on advanced hepatocellular carcinoma （HCC）. Methods： The study population consisted of 132 advanced HCC patients with Child-pugh NB. Tumor in all patients was involved with main trunk of portal vein and/or inferior vena cava, or local lymph node metastasis, or distant metastasis. TACE combined with ganfule were performed in 65 patients with advanced HCC （interventional treatment group）, 67 patients were treated with traditional Chinese herbal drug alone （Chinese herb group）. The prime end point was overall survival （OS）, and prognostic factors were analyzed. Results： The median OS was 205 days [95% confidence interval （CI）, 155-255 days] in interventional treatment group and 127 days （95% CI, 70-184 days） in Chinese herb group （P 〈 0.05）. The 6-month, 1-year, and 2-year OS rates were 58.9%, 29.1%, 7.7% in interventional treatment group, and 33.3%, 12.3%, 1.8% in Chinese herb group, respectively. The portal vein thrombosis, ECOG performance status （PS） were independent prognostic factors for OS. Conclusion： Ttranscatheter arterial chemoembolization combined with a Chinese compound preparation of ganfule could greatly prolong the OS of advanced HCC patients. The portal vein thrombosis and ECOG PS were independent prognostic factors for OS.
